Amy N. Solan, MD
Selective bladder preservation has been suggested as a potential alternative to cystectomy in patients with bladder cancer who have a transitional cell carcinoma pathology. The goal is to improve long-term quality of life without compromising oncologic outcomes, according to Amy N. Solan, MD, a clinical instructor in the Department of Radiation Oncology at NYU Langone Heath.
The current standard treatment for muscle-invasive bladder cancer is radical cystectomy with bilateral pelvic lymphadenectomy, with the addition of neoadjuvant cisplatin-based combination chemotherapy.
... to read the full story